Venous thrombotic events and impact on outcomes in patients treated with first-line single-agent pembrolizumab in PD-L1 ≥ 50% advanced non small cell lung cancer

[1] Amrane K(2020)First-line pembrolizumab for non-small cell lung cancer patients with PD-L1 ≥50% in a multicenter real-life cohort: The PEMBREIZH study Cancer Med. 9 2309-2316

[2] Geier M(2015)Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer N Engl J Med 373 1627-1639

[3] Corre R(2015)Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer N Engl J Med 373 123-135

[4] Léna H(2021)Anticoagulation therapy promotes the tumor immune-microenvironment and potentiates the efficacy of immunotherapy by alleviating hypoxia J Immunother Cancer 205 29-39

[5] Léveiller G(2021)Venous thrombotic events in patients treated with immune checkpoint inhibitors for non-small cell lung cancer: A retrospective multicentric cohort study Thromb Res 118 1392-1408

[6] Gadby F(2022)First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score >/= 50%) advanced non-small cell lung cancer in the real world: impact in brain metastasis: a national French multicentric cohort (ESCKEYP GFPC study) Cancer Immunol Immunother 154 28-34

[7] Borghaei H(2016)Cross talk pathways between coagulation and inflammation Circ Res 29 5417-5423

[8] Paz-Ares L(2017)Meta-analysis on anticoagulation and prevention of thrombosis and mortality among patients with lung cancer Thromb Res 160 809-815

[9] Horn L(2021)Poorer baseline performance status is associated with increased thromboembolism risk in metastatic cancer patients treated with immunotherapy Support Care Cancer 387 1540-1550

[10] Brahmer J(2000)Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study Arch Intern Med 208 71-78

[1] Amrane K(2020)First-line pembrolizumab for non-small cell lung cancer patients with PD-L1 ≥50% in a multicenter real-life cohort: The PEMBREIZH study Cancer Med. 9 2309-2316

[2] Geier M(2015)Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer N Engl J Med 373 1627-1639

[3] Corre R(2015)Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer N Engl J Med 373 123-135

[4] Léna H(2021)Anticoagulation therapy promotes the tumor immune-microenvironment and potentiates the efficacy of immunotherapy by alleviating hypoxia J Immunother Cancer 205 29-39

[5] Léveiller G(2021)Venous thrombotic events in patients treated with immune checkpoint inhibitors for non-small cell lung cancer: A retrospective multicentric cohort study Thromb Res 118 1392-1408

[6] Gadby F(2022)First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score >/= 50%) advanced non-small cell lung cancer in the real world: impact in brain metastasis: a national French multicentric cohort (ESCKEYP GFPC study) Cancer Immunol Immunother 154 28-34

[7] Borghaei H(2016)Cross talk pathways between coagulation and inflammation Circ Res 29 5417-5423

[8] Paz-Ares L(2017)Meta-analysis on anticoagulation and prevention of thrombosis and mortality among patients with lung cancer Thromb Res 160 809-815

[9] Horn L(2021)Poorer baseline performance status is associated with increased thromboembolism risk in metastatic cancer patients treated with immunotherapy Support Care Cancer 387 1540-1550

[10] Brahmer J(2000)Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study Arch Intern Med 208 71-78